To determine whether the increased levels of PD-1+ CD8+ T-cells may be a negative modulator for SMC efficacy, we also assessed blocking the checkpoint target, PD-1, as well as CTLA-4, in combination with SMC using two mouse models of glioblastoma. The gene discussed is CTLA4; the disease is glioblastoma.